Zofenopril: Blood pressure control and cardio-protection

Current hypertension guidelines suggest various strategies to reduce blood pressure levels, thereby reducing cardiovascular events: combinations of drugs with different mechanisms of action, such as an angiotensin converting enzyme inhibitors (ACEIs) and a diuretic, are the cornerstone of the modern treatment of hypertension, also as initial therapy. Among ACEIs, zofenopril has been shown to be effective in the management of hypertension both as monotherapy and in combination with a diuretic: zofenopril/hydrochlorothiazide fixed dose combination is particularly useful to improve treatment adherence through simplification of treatment regimen. Moreover, thanks to the sulfhydryl group, zofenopril has some peculiar properties (higher lipophilicity and tissue penetration, lower bradykinin-dependent effect, higher affinity for, and more persistent binding to, tissue ACE, significant antioxidant effect), which may account for the cardioprotective effects of the drug demonstrated in both pre-clinical studies and randomized clinical trials. The positive impact of zofenopril on clinical outcomes has been extensively documented by the SMILE program, including several clinical trials in patients with different conditions of myocardial ischemia treated with zofenopril: the results of the SMILE program, demonstrating the benefits of zofenopril vs. placebo and other ACEIs, emphasize the importance of a differentiated approach to patients with ischemic heart disease, based on a careful choice of the adopted agent, in order to improve the overall impact of pharmacological treatment on clinical outcomes

Stigma of People with HIV/AIDS in Sub-Saharan Africa: A Literature Review

The aim of this literature review is to elucidate what is known about HIV/AIDS and stigma in Sub-Saharan Africa. Literature about HIV/AIDS and stigma in Sub-Saharan Africa was systematically searched in Pubmed, Medscape, and Psycinfo up to March 31, 2009. No starting date limit was specified. The material was analyzed using Gilmore and Somerville's (1994) four processes of stigmatizing responses: the definition of the problem HIV/AIDS, identification of people living with HIV/AIDS (PLWHA), linking HIV/AIDS to immorality and other negative characteristics, and finally behavioural consequences of stigma (distancing, isolation, discrimination in care). It was found that the cultural construction of HIV/AIDS, based on beliefs about contamination, sexuality, and religion, plays a crucial role and contributes to the strength of distancing reactions and discrimination in society. Stigma prevents the delivery of effective social and medical care (including taking antiretroviral therapy) and also enhances the number of HIV infections. More qualitative studies on HIV/AIDS stigma including stigma in health care institutions in Sub-Saharan Africa are recommended

11 x 224 Gb/s POLMUX-RZ-16QAM transmission over 670 km of SSMF with 50-Ghz channel spacing

We demonstrate the generation and transmission of eleven channels with 224-Gb/s polarization-multiplexed, return to zero, 16-level quadrature amplitude modulation (POLMUX-RZ-16QAM) over 670 km of standard single mode fiber (SSMF) with 50-GHz channel spacing and a spectral efficiency of 4.2 b/s/Hz. We report a penalty of around 4.3 dB in the performance at back-to-back in comparison to the theoretical limits, and a margin of 1 dB in Q-factor below the forward error correction (FEC) limit (assumed to be at a bit error rate of 3.8x10-3) after transmission over 670 km of SSMF

A study of the remarkable galaxy system AM 546-324 (the core of Abell S0546)

We report first results of an investigation of the tidally disturbed galaxy system AM\,546-324, whose two principal galaxies 2MFGC 04711 and AM\,0546-324 (NED02) were previously classified as interacting doubles. This system was selected to study the interaction of ellipticals in a moderately dense environment. We provide spectral characteristics of the system and present an observational study of the interaction effects on the morphology, kinematics, and stellar population of these galaxies. The study is based on long-slit spectrophotometric data in the range of $\sim$ 4500-8000 $\AA$ obtained with the Gemini Multi-Object Spetrograph at Gemini South (GMOS-S). We have used the stellar population synthesis code STARLIGHT to investigate the star formation history of these galaxies. The Gemini/GMOS-S direct r-G0303 broad band pointing image was used to enhance and study fine morphological structures. The main absorption lines in the spectra were used to determine the radial velocity. Along the whole long-slit signal, the spectra of the Shadowy galaxy (discovered by us), 2MFGC 04711, and AM\,0546-324 (NED02) resemble that of an early-type galaxy. We estimated redshifts of z= 0.0696, z= 0.0693 and z= 0.0718, corresponding to heliocentric velocities of 20\,141 km s$^{-1}$, 20\,057 km s$^{-1}$, and 20\,754 km s$^{-1}$ for the Shadowy galaxy, 2MFGC 04711 and AM\,0546-324 (NED02), respectively. ..

Transmission of 11 x 224 Gb/s POLMUX-RZ-16QAM over 1500 km of LongLine and pure-silica SMF

We demonstrate transmission of 11 x 224-Gb/s POLMUX-RZ-16QAM over 1500 km with a channel spacing of 50 GHz. A hybrid configuration of LongLine and pure silica fiber is used to optimize both nonlinear tolerance and Raman gain.</p

Zofenopril: Blood pressure control and cardio-protection

Current hypertension guidelines suggest various strategies to reduce blood pressure levels, thereby reducing cardiovascular events: combinations of drugs with different mechanisms of action, such as an angiotensin converting enzyme inhibitors (ACEIs) and a diuretic, are the cornerstone of the modern treatment of hypertension, also as initial therapy. Among ACEIs, zofenopril has been shown to be effective in the management of hypertension both as monotherapy and in combination with a diuretic: zofenopril/hydrochlorothiazide fixed dose combination is particularly useful to improve treatment adherence through simplification of treatment regimen. Moreover, thanks to the sulfhydryl group, zofenopril has some peculiar properties (higher lipophilicity and tissue penetration, lower bradykinin-dependent effect, higher affinity for, and more persistent binding to, tissue ACE, significant antioxidant effect), which may account for the cardio-protective effects of the drug demonstrated in both pre-clinical studies and randomized clinical trials. The positive impact of zofenopril on clinical outcomes has been extensively documented by the SMILE program, including several clinical trials in patients with different conditions of myocardial ischemia treated with zofenopril: the results of the SMILE program, demonstrating the benefits of zofenopril vs. placebo and other ACEIs, emphasize the importance of a differentiated approach to patients with ischemic heart disease, based on a careful choice of the adopted agent, in order to improve the overall impact of pharmacological treatment on clinical outcomes